Progress in renal drug targeting

Yaoxue Xuebao

Volumn 40, Issue 3, 2005, Pages 199-203

  Zheng, Qiang ^a   Zhang, Zhi Rong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Low molecular weight protein; Prodrug; Promixal tubular cell; Renal drug targeting

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NAPROXEN; RIBONUCLEASE;

DRUG DELIVERY SYSTEM; DRUG TARGETING; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; REVIEW;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY TUBULES, PROXIMAL; MALEATES; MOLECULAR WEIGHT; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; POLYVINYLS; PRODRUGS; PROTEINS;

EID: 18244408505     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kitamura M, Fine LG. The concept of glomerular self-dense [J]. Kidney Int, 1999,55(5):1639-1671.
2. Burton CJ, Walls J. Proximal tubular cell, proteinuria and tubulo-interstitial scarring [J]. Nephron, 1994,68(3):287-293.
3. Johnson RJ. Cytokines, growth factors and renal injury: where do we go now? [J]. Kidney Int Suppl, 1997,63(12):S2-S6.
4. Manil L, Davin JC, Duchenne C, et al. Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro [J]. Pharm Res, 1994,11(8):1160-1165.
5. Kitamura M, Taylor S, Unwin R, et al. Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo [J]. J Clin Invest, 1994,94(2):497-505.
6. Pritchard JB, Miller DS. Comparative insights into the mechanisms of renal organic anion and cation secretion [J]. Am J Physiol, 1991,261(6):R1329- R1340.
7. Welbourne TC, Matthews JC. Glutamate transport and renal function [J]. Am J Physiol, 1999,277(4):F501-505.
8. Suzuki K, Susaki H, Okuno S, et al. Specific renal delivery of sugar-modified low-molecular-weight peptides [J]. Pharmacol Exp Ther, 1999,288(2):888-897.
9. Bode BP. Recent molecular advances in mammalian glutamine transport [J]. J Nutr, 2001,131(9):2475S-85S.
10. Christensen EI, Gburek J. Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology [J]. Pediatr Nephrol, 2004,19(7):714-721.
11. Zou Z, Chung B, Nguyen T, et al. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule [J]. J Biol Chem, 2004,279(33):34302-34310.
12. Van Ginneken CA, Russel FG. Saturable pharmacokinetics in the renal excretion of drugs [J]. Clin Pharmacol, 1989,16(1):38-54.
13. Pritchard JB, Miller DS. Comparative insights into the mechanisms of renal organic anion and cation secretion [J]. Am J Physiol, 1991,261(6):R1329- R1340.
14. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes [J]. Am J Physiol, 1996,270(4):G541-553.
15. Orlowski M, Wilk S. In vivo synthesis of ophthalmic acid in liver and kidney [J]. Biochem J, 1978,170(2):415-419.
16. Suzuki K, Susaki H, Okuno S, et al. Renal drug targeting using a vector "alkylglycoside" [J]. J Pharmacol Exp Ther, 1999,288(1):57-64.
17. Orlowski M, Wilk S. Metabolism of γ-glutamyl amino acids and peptides in mouse liver and kidney in vivo [J]. Eur J Biochem, 1976,71(2):549-555.
18. Wilk S, Mizoguchi H, Orlowski M. γ-Glutamyl dopa: a kidney-specific dopamine precursor [J]. J Pharmacol Exp Ther, 1978,206(1):227-232.
19. Pestana M, Soares-da-Silva P. The renal handling of dopamine originating from L-dopa and gamma-glutamyl-L-dopa [J]. Br J Pharmacol, 1994,112(2):417-422.
20. Mizoguchi H, Orlowski M, Wilk S, et al. Gamma-glutamyl DOPA and gamma-glutamyl dopamine: effect on plasma glucose levels [J]. Eur J Pharmacol, 1979,57 (2-3):239-245.
21. Orlowki M, Mizoguchi H, Wilk S. N-Acyl-γ-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs [J]. J Pharmacol Exp Ther, 1980,212(1):167-172.
22. Su M, He Q, Zhang ZR, et al. Kidney-targeting characteristics of N-acetyl-L-glutamic prednisolone prodrug [J]. Acta Pharm Sin, 2003,38(8):627-630.
23. Drieman JC, Thijssen HHW, Zeegers HHM, et al. Renal selective N-acetyl-γ-glutamyl prodrugs: a study on the mechanism of activation of the renal vasodilator prodrug CGP 22979 [J]. Br J Pharmacol, 1990,99(1):15-20.
24. Elfarra AA, Hwang IY. Metabolism and kidney-selectivity of S-(6-purinyl)-L-cysteine analogs in rats [J]. Drug Metab Dispos, 1993,21(5):841-845.
25. Birn H, Selhub J, Christensen EI. Internalization and intracellular transport of folate binding protein in rat kidney proximal tubule [J]. Am J Physiol, 1993,264(33):C302-C310.
26. 111In DTPA-folate for use as a tumor-targeted radiopharmaceutical [J]. Bioconjug Chem, 1997,8(5):673-679.
27. Clifford AJ, Heid MK, Muller HG, et al. Tissue distribution and prediction of total bodv folate of rats [J]. J Nutr, 1990,120(12):1633-1639.
28. Maack T, Johnson V, Kau ST, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review [J]. Kidney Int, 1979,16(3):251-270.
29. Maack T, Park CH, Camargo. Renal filtration, transport, and metabolism of proteins [A]. In The Kidney, Physiology and Pathophysiology [M]. New York: Raven Press, 1985. 1773-1803.
30. Christensen EI, Nielsen S. Structural and functional features of protein handling in the kidney proximal tubule [J]. Semin Nephrol, 1991,11(4):414-439.
31. Haas M, de Zeeuw D, Zanten AV, et al. Quantification of renal low-molecular-weight protein handling in the intact rat [J]. Kidney Int, 1993,43(4):949-954.
32. Haas M, de Zeeuw D. In vivo renal low-molecular-weight protein handling in the rat [J]. J Am Soc Nephrol, 1990,1(5):699.
33. Franssen EJF, Koiter J, Kuipers CAM, et al. Low molecular weight proteins for renal drug targeting: preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lystates [J]. J Med Chem, 1992,35(7):1246-1259.
34. Franssen EJF, Moolenaar F, de Zeeuw D, et al. Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid [J]. Pharmacol Res, 1993,10(7):963-969.
35. Franssen EJF, van Amsterdam RGM, Visser J, et al. Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme [J]. Pharm Res, 1991,8(10):1223-1230.
36. Haas M, Kluppel ACA, Watna ES, et al. Drug targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo [J]. Kidney Int, 1997,52(6):1693-1699.
37. Kok RJ, Grijpstra F, Walthuis RB, et al. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme [J]. J Pharmacol Exp Ther, 1999,288(1):281-285.
38. Folgert R, Haverdings G, Haas M. Renal targeting of catopril selectively enhances the intrarenal over the systematic effects of ACE inhibition in rats [J]. Br J Pharmacol, 2002,136(8):1107-1116.
39. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Poly (vinylpyrrolidone-co- dimethylmaleic acid) as a novel renal targeting carrier [J]. J Control Release, 2004,95 (2):229-237.
40. Kamada H, Tsumi Y, Sato-Kamada K, et al. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic acid) co-polymer and its application as renal targeting carier [J]. Nat Biotechnol, 2003,21(3):955-961.
41. Kodaira H, Tsutsumi Y, Yoshioka Y, et al. The targeting of anionized polyvinylpyrrolidone to the renal system [J] Biomaterials, 2004,25(18):4309- 4315.
42. Kishida A. A site-specific polymeric drug carrier for renal disease treatment [J]. Trends Pharmacol Sci, 2003,24(12):611-613.
43. Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney [J]. Eur J Pharmacol, 2003,479(1-3):269-281.
44. Van der Wouden EA, Sandovici M, Henning RH, et al. Approaches and methods in gene therapy for kidney disease [J]. J Pharmacol Toxicol Methods, 2004,50(1):13-24.
45. Noiri E, Peresleni T, Miller F, et al. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia [J]. J Clin Invest, 1996,97(10):2377-2383.
46. Oberbauer R, Schreiner GF, Biber J, et al. In vivo suppression of the renal Na/Pi cotransporter by antisense oligonucleotides [J]. Proc Natl Acad Sci USA, 1996,93(4):4903-4906.
47. Wang ZQ, Felder RA, Carey RM. Selective inhibition of the renal dopamine subtype D1A receptor induces antinatriuresis in conscious rats [J]. Hypertension, 1999,33(2):504-510.
48. Chen W, Bennnett CF, Wang ME, et al. Perfusion of kidneys with unformulated "naked" intercellular adhension molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury [J]. Transplantation, 1999,68(6):880-887.
49. Cheng QL, Chen XM, Li F, et al. Effects of ICAM-1 antisense oligonucleotide on the tubulointerstitium in mice with unilateral ureteral obstruction [J]. Kidney Int, 2000,57(1):183-190.
50. Okada H, Moriwaki K, Kalluri R, et al. Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration [J]. Am J Physiol, 2000,278(1):F110-F121.
51. Isono M, Mogyorosia A, Han DC, et al. Stimulation of TGF-type II receptor by high glucose in mouse mesangial cells and in diabetic kidney [J]. Am J Physiol, 2000,278(5):F830-838.